Stephen J. Schuster

Stephen J. Schuster, MD is a Professor of Medicine at the University of Pennsylvania's Perelman School of Medicine, where he serves as Director of the Lymphoma Program and Director of the Lymphoma Translational Research Program at the Abramson Cancer Center. He holds the distinguished position of Robert and Margarita Louis-Dreyfus Professor in Chronic Lymphocytic Leukemia and Lymphoma, reflecting his specialized expertise in this field. Dr. Schuster maintains clinical privileges at the Hospital of the University of Pennsylvania and is on the medical staff at Penn Presbyterian Medical Center.

Dr. Schuster's research focuses on advancing lymphoma treatment through innovative approaches, particularly in CAR-T cell therapy and translational research. His work has significantly contributed to establishing CAR-T cell therapy as a standard treatment option for relapsed or refractory lymphomas. He leads multiple clinical trials evaluating novel therapies and combination approaches for B-cell malignancies, with particular emphasis on understanding mechanisms of treatment resistance and developing predictive biomarkers.

Analysis of Dr. Schuster's recent publications (2021-2025) reveals a strong focus on optimizing CAR-T cell therapy for lymphoma patients, with significant contributions to understanding long-term outcomes, mechanisms of resistance, and strategies to improve treatment efficacy. His work spans both clinical trials and translational research, bridging laboratory findings with patient care.

• Robert and Margarita Louis-Dreyfus Professor in Chronic Lymphocytic Leukemia and Lymphoma
• Multiple high-impact publications in journals including New England Journal of Medicine, Lancet, and Blood
• Principal investigator for pivotal CAR-T cell therapy trials (JULIET, ELARA)

Dr. Schuster maintains an active clinical practice seeing patients aged 15-65 at the Abramson Cancer Center, with a patient satisfaction rating of 5.0 based on over 600 reviews. His clinical expertise complements his research leadership, allowing him to translate scientific discoveries into improved patient care for those with lymphoma and related hematologic malignancies.